Amarin Corporation Plc

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amarin reports robust Q4 earnings, eyes global expansion opportunities

Amarin's Q4 2022 earnings call highlighted strong financial performance, successful global expansion efforts, and a focus on cash preservation and talent acquisition. The company's UK launch milestones and international progress position it well for future growth.

Amarin reports Q1 revenue growth amidst pricing challenges and opportunities

Amarin focuses on revenue growth and cost-saving initiatives to drive operational efficiency and profitability.
The company's strong cash position provides stability for future growth initiatives and strategic investments.
Challenges include pricing pressure from generics and the need to balance expenses with revenue growth.
Opportunities lie in expanding prescription growth, product portfolio, and exploring strategic partnerships.

Amarin Corporation Plc reports robust Q3 earnings and strategic growth plans

Amarin Corporation Plc's Q3 2023 earnings call showcased strong financial performance, operational decisions driving positive cash flow, and a focus on maximizing shareholder value. While challenges in the European market and uncertainties around stock price were noted, opportunities for growth in global markets and strategic initiatives offer potential for future success.

Amarin reports solid Q4 revenue growth and eyes global expansion

Amarin's Q4 2023 performance reflects revenue growth and ongoing investment in strategic initiatives.
The company's strong financial position and operational momentum in key markets position it well for future growth.
Challenges around market dynamics, expenses management, and competition require strategic focus for sustained success.

Amarin reports stable Q1 earnings, focuses on European growth opportunities

Amarin Corporation's Q1 2024 earnings call highlighted solid financial performance, successful IP defense in Europe, and positive clinical outcomes for its key products. While facing challenges in the U.S. market due to generic competition, the company maintains profitability and a strong cash position. Opportunities lie in shareholder value enhancement and continued growth in Europe.

Amarin reports stable revenue but faces generic competition challenges

Amarin's Q2 2024 performance reflects revenue decline in the U.S. due to generic competition but improved net income from expense reductions. The company's strengths lie in the success of Vascepa/VAZKEPA and maintaining market share. Challenges include adapting to changing market dynamics, while opportunities exist in global expansion and strategic initiatives.

Amarin reports Q3 revenue of $42.3M, focuses on global expansion

Amarin's Q3 2024 performance reflects a mixed financial outcome with total net revenue of $42.3M and a GAAP net loss of $25.1M, impacted by challenges in the U.S. generic market.
Despite facing pricing pressures and cost reduction efforts, the company maintains a stable cash position of $306M and remains focused on global expansion.
The strengths lie in the proven science and support for VASCEPA/VAZKEPA, with opportunities to address the unmet need in reducing cardiovascular disease globally.
Challenges include navigating market dynamics and maintaining profitability amidst pricing pressures, while upcoming events signal proactive engagement for long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

The pharmaceuticals company is showing surprising resilience in the face of competition.

Why Amarin Is Soaring Today

Amarin Corporation plc's (AMRN) CEO Karim Mikhail on Q2 2021 Results - Earnings Call Transcript

Shares of Amarin Corp (NASDAQ:AMRN) rose 0.7% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 100.00% over the past year to $0.02, which beat the estimate of ($0.03).

Recap: Amarin Q2 Earnings

Commercial Launch of VAZKEPA in Europe on Track to Commence in September in Germany

Amarin Reports Second Quarter and Six Month 2021 Financial Results and Provides Business Update

Borqs Technologies

Dare Bioscience

Looking for penny stocks to watch in the second half of 2021? Check these 3 out The post Best Penny Stocks to Buy?

Best Penny Stocks to Buy? 3 to Watch In the Second Half of 2021

Amarin's (AMRN) second-quarter results are likely to reflect recovery in Vascepa sales amid potential recovery in COVID-19 related disruptions.

What's in the Cards for Amarin (AMRN) This Earnings Season?

Amarin Corporation plc is a global pharmaceutical company focused internationally on commercializing its sole therapeutic, Vascepa. Amarin's sole product is Vascepa, an icosapent ethyl-based cardiovascular therapeutic approved by the FDA, EMA, and various other government agencies around the globe for use in P-CVR.

Amarin: Is It A Buy, Sell, Or Hold? Buy For New Global Expansion

1847 GOEDEKER INC.

IAMGOLD

OMNIQ Corp

OPKO Health

Transocean

Wipro Limited Sponsored ADR

With Reddit's regular targets finally dropping, these stocks could be the next target for another crazy wave of Reddit Penny Stocks. The post 7 Reddit Penny Stocks About to Explode appeared first on InvestorPlace.

7 Reddit Penny Stocks About to Explode

DUBLIN, Ireland and BRIDGEWATER, N.J., July 15, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management to discuss the company's second quarter and six month 2021 financial results and provide an operational update on Thursday, August 5, 2021, at 7:30 a.m. ET. The conference call will follow the anticipated release of the company's financial results earlier that day.

Amarin to Report Second Quarter and Six Month 2021 Financial Results and Host Conference Call on August 5, 2021

Amarin stock surpassed the 75% upside price target in Feb., only to fall from there. Unfavorable Patent ruling expected.

Why Amarin Stock May Rise From Here

Another Vascepa generic is launched in the U.S.

Why Amarin Fell Again Today

Cocrystal Pharma

Elite Education Group International Ltd

Luokung Technology Corp

Meten Holding Group Ltd.

NovaBay Pharmaceuticals

Regulus Therapeutics

Which penny stocks are worth buying next month? Check these 7 out for your watchlist The post 7 Hot Penny Stocks to Watch That Are Trending Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

7 Hot Penny Stocks to Watch That Are Trending Right Now

Aeterna Zentaris

DURECT

Globus Maritime

CarLotz

MediWound

Intec Parent

What are the best penny stocks to buy this week? The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 7 To Watch This Week

Goldman Sachs

Amarin Corporation plc (AMRN) CEO John Thero Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript)

Studies support potentially important anti-inflammatory, protein modulation, and cell function effects of icosapent ethyl as known by the brand name VASCEPA® in much of the world and as VAZKEPA in Europe Studies support potentially important anti-inflammatory, protein modulation, and cell function effects of icosapent ethyl as known by the brand name VASCEPA® in much of the world and as VAZKEPA in Europe

Further Insights into Mechanism of Action of Icosapent Ethyl and Its Unique Form of Eicosapentaenoic Acid (EPA) Presented at the European Atherosclerosis Society (EAS) Congress 2021

Amarin Corporation's (AMRN) CEO John Thero on Jefferies Virtual Healthcare Conference - Transcript

Investors reacted positively to a company presentation at an industry convention.

Why Amarin Trounced the Market on Tuesday

DUBLIN, Ireland and BRIDGEWATER, N.J., May 18, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, and Karim Mikhail, Amarin's senior vice president and head of commercial for Europe and future president and chief executive officer, are scheduled to present at the following investor conferences scheduled in June:

Amarin to Present at Two Investor Conferences in June 2021

REDUCE-IT® patients experienced substantial cardiovascular (CV) risk reduction with icosapent ethyl regardless of the presence or degree of dyslipidemia, as defined by various high TG plus low HDL-C levels

Amarin Highlights Multiple Scientific Findings for VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient at the American College of Cardiology's 70th Annual Scientific Session

Post hoc analyses by estimated on-treatment serum EPA levels in the VASCEPA group suggest potentially reduced incidence of new heart failure and new heart failure requiring hospitalization with higher achieved serum EPA levels

REDUCE-IT® Heart Failure Analyses by VASCEPA® (Icosapent Ethyl)-Driven Serum Eicosapentaenoic Acid (EPA) Levels Suggest Potential Benefit in New Heart Failure in Studied At-Risk Patients as Presented at the American College of Cardiology's 70th Annual Sci

Why Amarin Stock Is Tumbling Today

Amarin-Supported Research and Analyses from Academic Collaborators to Be Featured in Seven Presentations, Including REDUCE-IT® Heart Failure and Additional Analyses from EVAPORATE Amarin-Supported Research and Analyses from Academic Collaborators to Be Featured in Seven Presentations, Including REDUCE-IT® Heart Failure and Additional Analyses from EVAPORATE

Clinical Data and Other Research Results Regarding VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient to Be Presented at the American College of Cardiology's 70th Annual Scientific Session

Amarin Corporation PLC (AMRN) CEO John Thero on Q1 2021 Results - Earnings Call Transcript

Amarin's (AMRN) Vascepa sales get hit by COVID-19 and by severe winter storms and power outages in various areas of the United States. Its cost management plan boost the bottom line.

Amarin (AMRN) Q1 Earnings Top, Vascepa Sales Hit by COVID-19

Shares of Amarin Corp (NASDAQ:AMRN) rose 2.5% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 100.00% over the past year to ($0.00), which beat the estimate of ($0.05).

News for Amarin Corporation Plc Stock (AMRN)